Medical Oncology
Despite significant advances in the understanding of renal cell carcinoma (RCC), the management of this malignancy remains a therapeutic challenge. Malignant tumors of the kidney and renal pelvis constitute 2% to 3% of all new cancer cases in the United States. The median age of diagnosis is 66 years, with highest incidence in the seventh decade. The incidence of RCC is much higher in developed countries, which may be reflective of environmental factors and the widespread use of noninvasive abdominal imaging modalities (eg, MRI, CT scanning, or ultrasound) that detect incidental, asymptomatic tumors. Despite increased detection of incidental tumors, 25% to 30% of patients with RCC have distant metastasis at presentation. Forty percent of patients, like the patient in this clinical scenario, who undergo surgical resection for a primary RCC eventually develop metastasis. Although the overall survival rate of RCC at 5 years is approximately 50%, those patients with metastatic disease have a median survival duration of only 7 to 11 months. However, the median survival is dependent on the prognostic group of the patient. 1 The 2-year survival with metastases within 1 year of nephrectomy for primary RCC is poor. RCC is a frequent cause of cancer mortality and is responsible for close to 12,000 deaths per year.
A number of studies have investigated environmental and genetic risk factors for the development of RCC. Cigarette smoking has been identified as the major risk factor. Obesity, hypertension, polycystic kidney disease, and high-protein diets have also been consistently associated with RCC. Other potential risk factors include renal transplantation, HIV, heavy metals such as cadmium and lead, chlorinated solvents, asbestos, and phenacetin analgesics. 2 The recognition of familial patterns of RCC has resulted in interest in the genetics of this malignancy. Molecular genetic studies involving many RCC cases have shown a chromosome 3 abnormality (deletions, translocations, and rearrangements). The loss of the segment of the short arm of chromosome 3 (3p) is the most consistent finding in clear cell carcinomas. Studies performed on von Hippel-Lindau disease, the form of RCC associated with an inherited cancer syndrome, further determined that the von Hippel-Lindau gene maps to the distal region of chromosome 3p. The product(s) of the VHL gene may have important regulatory roles at the cellular level and have been linked to loss of suppression of the vascular endothelial growth factor (VEGF), which may lead to tumor angiogenesis. 3 Both sporadic and VHL-associated RCC are highly vascular tumors. Sporadic cases of clear cell RCC have also been associated with mutations in the VHL gene.
RCC arises from the proximal renal tubular epithelium typically in the renal cortex and can extend into medullary structures, the renal vein, and even the inferior vena cava. The most common presentation is a solitary renal mass (although bilateral renal tumors occur). RCC can present with the classic triad of hematuria, flank pain, and palpable mass, although these symptoms can present in any course of the disease process, as in our patient. Among patients with metastasis, the lungs, lymph nodes, soft tissue, bone, adrenals, and liver are the most common sites of disease. However, patients may also have metastasis involving the central nervous system and skin. Most renal cell tumors are a combination of cell types including clear and granular cells. The sarcomatoid variant-containing spindle cells and those malignant tumors with a papillary pattern are associated with a poorer prognosis.
Prognosis of patients with RCC is affected by tumor stage, tumor grade, and patient performance and other factors. The 2 most common staging systems are the Robson modification of the system described by Flocks and Kadesky and the TNM system (tumor[size], [lymph]node, and metastasis). 4 The Robson classification stratifies patients into categories of extent of local disease (ie, stage I = disease confined to the renal parenchyma, stage II = extension into perirenal fat, stage III = involvement of vascular structures and/or lymph nodes, stage IV = involvement of adjacent organs or distant metastasis). Despite the fact that the Robson modification system is widely used, the TNM system, now modified to reflect also vascular spread, is a better prognostic indicator and correlates with survival throughout all stages. For example, tumor size has been associated with patient outcome, and this is reflected in the TNM rather than the Robson classification methods. Tumor grade, especially nuclear size, shape, and content, is also a valuable prognostic indicator. The Karnofsky or Eastern Cooperative Group patient performance scale measures the impact of overall objective and subjective symptoms and are often used as a part of eligibility criteria in clinical trials. Patients who have better performance statuses and are thus less debilitated by the cancer have been shown to have better survival rates. In addition to performance status, additional factors such as time from diagnosis to metastasis, location and number of metastatic sites, weight loss, and previous nephrectomy influence prognosis. 1, 5 Surgery is the only effective method for treating primary localized RCC. The goal of nephrectomy is to remove all tumor with adequate surgical margins. Radical nephrectomy involves renal artery ligation and excision of the kidney, adrenal gland, and lymph node dissection. By removing all of the contents of the Gerota's fascia, a wide margin away from the tumor can be achieved. With the advent of better imaging techniques such as high-resolution CT scanning, the need to undergo full radical nephrectomy in all cases has been questioned. For example, now many patients, due to be better staging, can undergo adrenalsparing radical nephrectomy with good outcomes. In addition, an increase in the number of incidental RCCs has recently led to new surgical techniques. Although nephron-sparing surgery had been previously recommended only in selected patients (eg, those with a solitary kidney, bilateral kidney tumors, or poorly functioning contralateral kidney), partial open nephrectomy is being offered more frequently. Partial nephrectomy can also be performed through laparoscopic techniques. These new surgical techniques have now been shown to have low morbidity with preservation of renal function and are associated, in many cases, with low incidence of local recurrence and long-term cure.
The patient in our case, who is 61 years old, is at an age when the incidence of RCC is high. Her initial presentation of her cancer was flank pain and hematuria, a common presentation for RCC. Her CT scan revealed a 7-cm tumor with thrombus. Both the tumor size (7 cm is the cutoff between stage T1 and T2) and presence of thrombus are associated with poorer prognosis. This patient did undergo surgery with a right radical nephrectomy, which was appropriate. Her margins were negative, and there were no sarcomatous features histologically. Her risk factors for RCC may include hypertension and a history of smoking. She has no family history of RCC or evidence of a von Hippel-Lindau-type syndrome (familial syndrome involving malignancies of cerebellum, spinal cord, kidneys, adrenals, pancreas, and retina). Unfortunately, this patient developed metastatic disease less than a year after her nephrectomy. However, she is still active with a good performance status.
The role of immunotherapy in metastatic RCC has grown over the past decade. The basis for treatment of RCC by manipulation of the immune system stemmed from observations that metastases may regress following nephrectomy presumably as a consequence of a patient's enhanced immune response against the tumor(s). The incidence of spontaneous regression, however, is thought to be low (less than 1%) and is not thought to be a reason for nephrectomy in RCC patients with multiple areas of metastases. However, the role of nephrectomy in persons with metastatic disease has been a source of debate in the modern area of immunotherapy. A number of studies have recently shown that nephrectomy plus immuno-therapy is superior to immunotherapy alone in terms of progression and survival in patients with metastatic RCC and good performance status. Nephrectomy in these patients also helps with palliation of symptoms such as pain, hematuria, and high calcium levels. If the patient in our clinical scenario clearly had metastatic disease at presentation, nephrectomy prior to any systemic therapy should still have been strongly considered.
Immunotherapy is the mainstay of treatment for patients with RCC and multiple areas of metastatic disease. The course of metastatic disease is variable in RCC. Although sometimes there is rapid progression, long-term stabilization of disease or remissions with therapy can occur. Interferons are a family of proteins produced by cells in response to viral infections. They have antitumor properties by direct inhibition of tumor cells and by augmentation of the immune system's recognition and targeting of tumor cells. Immunotherapy studies with interferon-α (INF-α) were the first performed and resulted in responses of 10% to 30% with a median duration of 10 months in selected patients with RCC. 6 Although long-term complete responders have been described, duration of response rarely exceeds 2 years. INF-α is produced in large quantities through recombinant DNA techniques, which can be administered through subcutaneous, intramuscular, or intravenous means with equal efficacy. The best schedule and dose has never been clearly established. Combinations of INF-α with chemotherapy or hormonal therapies have not been clearly shown to be more effective than INF-α alone. Side effects of INF-α include fever, chills, malaise, and headaches acutely. Delayed symptoms include nausea/ vomiting, anorexia, and fatigue. Depression, low blood counts, neurotoxicity, and thyroid and liver problems can occur.
Treatment of metastatic RCC with recombinant interleukin-2 (IL-2) has proven capable of producing long-term durable remissions in this difficult disease. IL-2 is a potent growth factor for T and natural-killer T-cell lymphocytes, which is the presumed antitumor mechanism. Several studies have been published revealing response rates from 7% to 23%, with one third of patients achieving complete remission. Duration of partial response is 12 to 19 months. In many studies, median duration of complete responses has not yet been reached. In a database of 255 patients, median survival was 16.3 months, with 10% to 20% alive 5 to 10 years after treatment. 7 A small subset of patients remained alive at 11 years after treatment. As a result of the data supporting the increased remission rates and survival with IL-2, the FDA approved the use of IL-2 for the treatment of RCC in 1992.
Toxicity of IL-2 is higher than that of interferon-α and is dependent on dose and schedule used. IL-2 can cause a capillary leak syndrome resulting in low blood pressure, fluid retention, and renal dysfunction. Severe cardiopulmonary (eg, requiring mechanical ventilation), hematologic, and gastrointestinal toxicities (eg, nausea, vomiting, anorexia, bowel infarction/ perforation) can be seen. Other complications include endocrine, dermatologic, and neurotoxicities along with a sepsis-like syndrome. Although most side effects are reversible following termination of treatment, IL-2 is associated with high drug-related death rates (usually 0%-2%). As a result, patient selection is important and should include those with ECOG performance status of 0, little or no comorbidity, and good cardiac, respiratory, and renal function.
Dosing and administration schedules of IL-2 in the clinical setting are variable and have been made in an attempt to reduce toxicity while maintaining efficacy. These approaches include short intravenous infusion either high or low dose, continuous intravenous infusion, or subcutaneous administration. There have been promising response rates with lower dose or subcutaneously administered therapies that have better tolerability; however, there is not enough data support durability of response with these approaches. Although associated with high toxicity, high-dose bolus IL-2 treatment is associated with prolonged and durable response rates not yet demonstrated with alternative approaches. 8 The combination of IL-2 with other therapies has been investigated. Studies with IL-2 in combination with INF-α have resulted in similar response rates to IL-2 alone. The toxicities of both have been shown to be additive. In one study, a higher response rate was achieved with this combination, but there was no survival benefit and toxicity was more severe. IL-2 in other combinations with chemotherapy has also resulted in little overall benefit in response or survival and greater toxicity. Multiple other studies of IL-2 in combination with other compounds (eg, retinoids, indomethaicin, cimetidine, melatonin) have been conducted without demonstrating any additional benefit.
The role of chemotherapy, hormone therapy, and radiation as treatment for metastatic RCC is limited. Metastatic RCC has been traditionally resistant to cytotoxic chemotherapy. The multidrug resistance gene and its protein product (P-glycoprotein) are highly expressed in RCC. No chemotherapy has produced adequate response rates to justify use as a single agent. There are clinical trials studying combination chemotherapy regimens (eg, gemcitabine in combination with capecitabine) in patients failing immunotherapy. All chemotherapy regimens at this time should be considered experimental. Hormonal therapy alone and in combination with immunotherapy has proven to be ineffective. In addition, RCC is less sensitive to radiation treatment than other solid tumors, and this modality should be used only for palliation in patients with symptomatic metastasis.
There is a great need for continued research in metastatic RCC, and clinical trials are available. Identification of new agents with activity against metastatic disease is paramount. Investigations with the use of monoclonal antibodies, tumor vaccines, dendritic cell therapies, and angiogenesis inhibitors are ongoing. Clear cell carcinomas express epidermal growth factor receptor and an antigen called G250, which are being targeted by monoclonal antibody therapies. Dendritic cells are loaded with tumor antigens and induce T-cell lymphocytes to target tumor cells after host vaccination. RCC is highly vascular and theoretically an ideal target for angiogenesis inhibitors. There is also some promise with stem cell transplantation in patients with metastatic RCC that is refractory to other treatments, although this treatment can be associated with high toxicity.
The patient in our clinical scenario has developed multiple metastatic sites of disease including the lungs and adrenal gland. In addition, the back pain she is experiencing and the skin nodules on her shoulder likely can be attributed to RCC. This patient, although experiencing pain, has an overall good performance status and is active. High-dose intravenous recombinant IL-2 alone seems to be superior to other regimens and has a higher incidence of complete remission and more durable response time when compared to INF-α. This patient is a good candidate for highdose IL-2 in that she has a good performance status, little comorbidity, good cardiopulmonary and renal function, and no liver metastasis. Although high-dose IL-2 should be offered, the rapid progression to metastatic disease after nephrectomy (1 year) and the presence of multiple metastatic sites have been associated with poorer outcome with this therapy. Due to the high toxicity of high-dose IL-2 therapy, other options should be offered and include phase I or phase II clinical trials with novel investigational drugs (such as the VEGF inhibitor phase I trial offered) alone or in combination with immunotherapy. Our therapeutic approach would depend on patient factors, outcome expectation, and patient acceptance. Palliative measures alone and/or observation alone are options and would be considered if the patient prefers this approach; however, because selected patients have shown complete and durable regression of tumors with immunotherapy, this modality of treatment should be strongly considered alone or in combination with new investigational approaches.
In addition to systemic therapy considerations, symptom control and palliation of symptoms are necessary. This patient has developed pain in the left scapula that could be due to bony metastasis. Pain control with medication is important to maintain activity levels and allow the patient to continue to perform her daily activities. A bone scan would help with the diagnosis of bony metastasis. If bony metastases are indeed present, there is evidence to support the use of monthly intravenous bisphosphonate use (eg, zolendronate) to help with symptoms and prevent further bony disease. In addition, our patient is experiencing weight loss. This has been associated with poorer prognosis, and efforts to promote proper nutrition and weight stabilization should be undertaken. Our patient is very anxious and may be depressed; both of these factors could contribute to her weight loss and insomnia. Psychological counseling and/or introduction to support groups may help. This patient should also be offered an antidepressant with anxiolytic properties to help with symptoms. Immunotherapy, if chosen, has been found to worsen fatigue, anxiety, and depression, and these symptoms should be addressed prior to starting any systemic therapy.
